| pubmed-article:18498916 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C1709854 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0022646 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0450127 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0026933 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0332157 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C1705413 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C1514721 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0016441 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C0521116 | lld:lifeskim |
| pubmed-article:18498916 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:18498916 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18498916 | pubmed:dateCreated | 2008-5-23 | lld:pubmed |
| pubmed-article:18498916 | pubmed:abstractText | Two recent randomized clinical trials--Fixed Dose Versus Concentration Controlled and the Apomygre--evaluating the benefit of therapeutic drug monitoring of mycophenolate mofetil (MMF) in renal allograft recipients reported conflicting results. In both studies, target mycophenolic acid (MPA) AUC(0-12 h) ranges (ie, values used to guide MMF dosing) were derived from a previous study establishing target MPA AUC(0-12 h) ranges in cyclosporine-treated patients between 30 and 60 mg/L x h(-1). Both studies found an association between MPA exposure and acute rejection. However, only one of the studies found concentration-controlled MMF dosing to be significantly associated with less biopsy-proven acute-rejection episodes compared with fixed dosing. No reduced incidence of MMF-related adverse events (AEs) was observed in either of the 2 trials when MMF concentration-controlled and fixed dosing were compared. | lld:pubmed |
| pubmed-article:18498916 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18498916 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18498916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18498916 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18498916 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:18498916 | pubmed:issn | 0149-2918 | lld:pubmed |
| pubmed-article:18498916 | pubmed:author | pubmed-author:Vanrenterghem... | lld:pubmed |
| pubmed-article:18498916 | pubmed:author | pubmed-author:KuypersDirk... | lld:pubmed |
| pubmed-article:18498916 | pubmed:author | pubmed-author:NaesensMaarte... | lld:pubmed |
| pubmed-article:18498916 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:18498916 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:18498916 | pubmed:author | pubmed-author:HalewijckEvel... | lld:pubmed |
| pubmed-article:18498916 | pubmed:author | pubmed-author:DekensMarcM | lld:pubmed |
| pubmed-article:18498916 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18498916 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:18498916 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18498916 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18498916 | pubmed:pagination | 673-83 | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:meshHeading | pubmed-meshheading:18498916... | lld:pubmed |
| pubmed-article:18498916 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18498916 | pubmed:articleTitle | Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. | lld:pubmed |
| pubmed-article:18498916 | pubmed:affiliation | Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium. Dirk.Kuypers@uz.kuleuven.ac.be | lld:pubmed |
| pubmed-article:18498916 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18498916 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18498916 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| entrez-gene:1244 | entrezgene:pubmed | pubmed-article:18498916 | lld:entrezgene |
| entrez-gene:54658 | entrezgene:pubmed | pubmed-article:18498916 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18498916 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18498916 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18498916 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18498916 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18498916 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18498916 | lld:pubmed |
